Novo Nordisk's Profit Warnings and Stock Drop Amid Competition and Guidance Cuts
TL;DR Summary
Novo Nordisk's shares plummeted over 22% after the company issued a profit warning due to intense US market competition and slower-than-expected sales growth for its weight-loss drugs Ozempic and Wegovy, leading to a significant reduction in its full-year sales and profit forecasts, amid ongoing legal actions against copycat drugs.
Topics:top-news#business#novo-nordisk#profit-warning#share-price-drop#us-competition#weight-loss-drugs
- Novo appoints new CEO as it slashes profit forecast Financial Times
- Novo Nordisk shares plunge 17% after Wegovy-maker cuts full-year guidance CNBC
- Obesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook Yahoo Finance
- Novo Nordisk Stock Plummets After Ozempic, Wegovy Maker Cuts U.S. Outlook Barron's
- Novo Nordisk issues profit warning as competition — legal and otherwise — hits Wegovy, Ozempic MarketWatch
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
84%
302 → 49 words
Want the full story? Read the original article
Read on Financial Times